---
document_datetime: 2025-10-17 10:49:33
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/sapropterin-dipharma-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: sapropterin-dipharma-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.6284226
conversion_datetime: 2025-12-29 21:07:14.969437
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Sapropterin Dipharma

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                           |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------------|
| Variation type IB /  | C.I.11 Introduction of, or change(s) to, the | 17/10/2025                          | N/A                                         |                                  | To update the RMP by removing all safety concerns |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000301290                     | obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted C.I.11.z (Type IB) - To update the RMP by removing all safety concerns in alignment with the RMP of the reference product, Kuvan. In addition, the MAH updated the RMP to reflect the change in the MAH's name and to align with the GVP Module V Rev. 2 template.   |            |     |             | in alignment with the RMP of the reference product, Kuvan.   |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|--------------------------------------------------------------|
| Variation type IA / EMA/VR/0000300572 | B.I.a.3 Change in batch size (including batch size ranges) of active substance or intermediate used in the manufacturing process of the active substance - B.I.a.3.a Up to 10-fold increase compared to the originally approved batch size - Accepted                                                                                                                                                                                            | 24/09/2025 | N/A |             |                                                              |
| Variation type IB / EMA/VR/0000247063 | This was an application for a group of variations. B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product - B.II.b.5.z Other changes - Accepted B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.z Other changes -                                                                                                                                 | 20/02/2025 |     | SmPC and PL |                                                              |

<div style=\"page-break-after: always\"></div>

| Accepted   |
|------------|